MYD88 was shown to interact with IRAK1 and IRAK4 and activate the NF-κB and JAK-STAT3 pathways, promoting malignant cell proliferation and causing worse survival of DLBCL patients (34). Here, IRAK4 is linked to diffuse large B-cell lymphoma.